Scholar Rock (SRRK) Competitors $40.91 +0.93 (+2.33%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRRK vs. ITCI, GMAB, MRNA, RDY, VTRS, QGEN, ASND, BBIO, VRNA, and BPMCShould you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Scholar Rock vs. Its Competitors Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories Viatris Qiagen Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Do institutionals & insiders have more ownership in ITCI or SRRK? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to ITCI or SRRK? In the previous week, Scholar Rock had 12 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 12 mentions for Scholar Rock and 0 mentions for Intra-Cellular Therapies. Scholar Rock's average media sentiment score of 0.75 beat Intra-Cellular Therapies' score of 0.29 indicating that Scholar Rock is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral Scholar Rock Positive Do analysts rate ITCI or SRRK? Intra-Cellular Therapies presently has a consensus price target of $109.70, indicating a potential downside of 16.81%. Scholar Rock has a consensus price target of $42.67, indicating a potential upside of 4.29%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is ITCI or SRRK more profitable? Scholar Rock has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Scholar Rock N/A -118.22%-82.01% Which has more risk and volatility, ITCI or SRRK? Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Which has better earnings & valuation, ITCI or SRRK? Intra-Cellular Therapies has higher revenue and earnings than Scholar Rock. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Scholar Rock$33.19M117.04-$246.29M-$2.53-16.17 SummaryScholar Rock beats Intra-Cellular Therapies on 10 of the 17 factors compared between the two stocks. Get Scholar Rock News Delivered to You Automatically Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRRK vs. The Competition Export to ExcelMetricScholar RockMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.89B$3.01B$5.61B$9.42BDividend YieldN/A2.49%4.01%4.02%P/E Ratio-16.2020.7728.3620.00Price / Sales117.04267.98414.8086.63Price / CashN/A41.6635.9658.29Price / Book10.388.018.425.73Net Income-$246.29M-$55.10M$3.24B$258.18M7 Day Performance-0.58%6.99%4.13%3.46%1 Month Performance22.93%21.04%12.22%14.30%1 Year Performance344.67%4.45%34.98%18.46% Scholar Rock Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRRKScholar Rock3.2763 of 5 stars$40.91+2.3%$42.67+4.3%+333.6%$3.89B$33.19M-16.20140Analyst RevisionITCIIntra-Cellular Therapies0.9985 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0414 of 5 stars$21.46+0.3%$37.80+76.1%-21.6%$13.77B$3.12B12.192,682Analyst DowngradeMRNAModerna4.2672 of 5 stars$32.87-2.3%$46.61+41.8%-73.3%$12.71B$3.24B-3.775,800Analyst ForecastRDYDr. Reddy's Laboratories2.9656 of 5 stars$14.58+0.4%$16.95+16.3%-9.9%$12.17B$325.54B22.0827,811Upcoming EarningsVTRSViatris2.4735 of 5 stars$9.14+0.2%$10.40+13.8%-20.8%$10.73B$14.74B-2.8832,000QGENQiagen3.7414 of 5 stars$48.25+0.3%$49.40+2.4%+20.5%$10.73B$1.98B120.985,765Positive NewsASNDAscendis Pharma A/S3.618 of 5 stars$174.880.0%$223.07+27.6%+21.4%$10.69B$393.54M-27.851,017Positive NewsBBIOBridgeBio Pharma4.6109 of 5 stars$47.69+2.6%$61.20+28.3%+71.6%$9.06B$221.90M-13.51400Upcoming EarningsAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.716 of 5 stars$104.67-0.2%$109.00+4.1%+359.0%$8.91B$42.28M-52.3430High Trading VolumeBPMCBlueprint Medicines1.0101 of 5 stars$129.36+0.0%$128.25-0.9%N/A$8.35B$508.82M-52.37640Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies ITCI Competitors GMAB Competitors MRNA Competitors RDY Competitors VTRS Competitors QGEN Competitors ASND Competitors BBIO Competitors VRNA Competitors BPMC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRRK) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scholar Rock Holding Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Scholar Rock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
